IRADIMED Corporation (NASDAQ: IRMD) — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; unaudited. IRADIMED develops, manufactures and sells MRI-compatible medical devices, accessories, disposables and related services, primarily to hospitals and acute care facilities.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | $15.48 million | $12.31 million; up 25.7% |
| Gross profit and margin | $11.72 million; 75.7% | $9.38 million; 76.2% |
| Operating income | $4.01 million | $3.07 million |
| Net income | $3.41 million | $2.49 million |
| Diluted EPS | $0.27 | $0.20 |
| Cash from operating activities | $4.65 million | $1.43 million |
| Cash and cash equivalents at period end | $42.78 million | $57.96 million at December 31, 2022 |
- Revenue growth came from U.S. sales, up 20.0% to $11.98 million, and international sales, up 49.9% to $3.50 million. Device revenue rose 24.3% to $10.54 million; disposables, services and other revenue rose 33.5% to $4.43 million.
- Gross margin fell 0.5 percentage point, which management attributed to unfavorable overhead variance, sales mix and inflation-related raw-material costs. General and administrative expense increased 44.4% to $3.92 million, primarily on higher legal, professional, payroll and benefit costs. Research and development expense increased 52.9% to $0.79 million, partly reflecting consulting for a next-generation pump.
- Other income was $0.34 million, compared with a $0.01 million expense a year earlier, primarily due to interest on money-market fund investments. The effective tax rate was 21.7%, versus 18.7%.
- Working capital was $54.5 million. Total liabilities were $11.28 million, including $2.76 million of operating lease liabilities. The filing reports no borrowings or material off-balance-sheet arrangements.
- Cash declined by $15.18 million, including $6.56 million used in investing and $13.27 million used in financing. The company paid a $13.22 million special dividend ($1.05 per share) and purchased land for $6.20 million.
Outlook, risks and notable items
- Management expects higher revenue for the remainder of 2023 than in the comparable 2022 period, driven by device, accessory, disposable and service sales; it also expects higher operating expenses, primarily general and administrative and sales and marketing costs. No quantified revenue or earnings guidance is provided.
- Management expects a full-year 2023 effective tax rate of approximately 22% and believes current cash and operating cash generation will meet requirements for at least 12 months.
- The company plans to develop the acquired 26.5-acre Florida property for manufacturing, research laboratories and office space over the next two years, using available cash. Purchase orders for goods and services totaled $11.42 million; balance-sheet amounts associated with them were immaterial.
- Key disclosed risks include dependence on a limited product range, FDA and other regulatory clearances, sole-sourced components, product and manufacturing risks, competition, and foreign-exchange exposure. A 10% yen movement was estimated to have an immaterial net-income effect for the quarter. The company also notes that cash balances regularly exceed federally insured limits.
- The company accrued approximately $250,000 for various legal matters, up from zero at year-end; management said known matters were not expected to materially affect results or financial position. Its manufacturing and headquarters lease is with an entity controlled by CEO and Chairman Roger Susi; rent paid in Q1 2023 was $127,817.
- Management reported effective disclosure controls and no material changes to internal control over financial reporting. The filing says there were no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Reconcile the MD&A financial highlights, which state revenue of $15.2 million and pretax income of $4.6 million, with the financial statements showing revenue of $15.475 million and pretax income of $4.350 million.
- Track whether revenue growth—particularly international sales and the infusion-pump and monitoring-device mix—continues, and whether gross-margin pressure from costs and overhead persists.
- Assess the cash impact and timing of the planned facility development alongside the special dividend, capital spending and purchase commitments.
- Monitor FDA and other regulatory developments, sole-source component availability, and the accrued legal matters.
- Consider the related-party lease and the company’s reliance on cash balances that exceed federal deposit-insurance limits.